Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sheryl Goodall

Clinical Nurse Specialist, Psychiatric/Mental Health, Adult Brockton, MA Clinical Nurse Specialist

NPI 1518948629 CMS profile 11155733

830 Oak St, Suite 105W, Brockton, MA 02301

Open in the dashboard

General payments

$3,910

240 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sheryl Goodall of Brockton, MA is reported in the CMS Open Payments database as having received $3,910 across 240 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Clinical Nurse Specialist, Psychiatric/Mental Health, Adult profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $282 23
2024 General $1,218 53
2023 General $811 44
2022 General $883 52
2021 General $716 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sheryl Goodall
  • Clinical Nurse Specialist, Psychiatric/Mental Health, Adult median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health, Adult
  • National median

In program year 2025, general payments to Sheryl Goodall were reported at $282. Among 197 Clinical Nurse Specialist, Psychiatric/Mental Health, Adult profiles paid that year, the median was $174 and the middle half received between $71 and $653.

Show as a table
Year Sheryl Goodall Clinical Nurse Specialist, Psychiatric/Mental Health, Adult median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $716 $152 $38–$472 $132
2022 $883 $172 $73–$546 $149
2023 $811 $156 $56–$560 $160
2024 $1,218 $158 $39–$521 $164
2025 $282 $174 $71–$653 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,028 55 payments
  2. ITI, Inc. $951 61 payments
  3. Otsuka America Pharmaceutical, Inc. $477 28 payments
  4. Alkermes, Inc. $387 22 payments
  5. Sunovion Pharmaceuticals Inc. $342 20 payments
  6. Axsome Therapeutics, Inc. $295 7 payments
  7. Lundbeck LLC $168 28 payments
  8. Corium, Inc. $108 10 payments
  9. Teva Pharmaceuticals USA, Inc. $63 4 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $36 2 payments
  11. Other $57 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,831 234 payments
  2. Education $79 6 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $964 52 payments
  2. CAPLYTA $814 47 payments
  3. REXULTI $477 28 payments
  4. LYBALVI Cns $387 22 payments
  5. LATUDA $342 20 payments
  6. LYBALVI Cns $304 13 payments
  7. Auvelity $295 7 payments
  8. LYBALVI Cns $215 3 payments
  9. LYBALVI Cns $215 3 payments
  10. ARISTADA $172 19 payments
  11. Other $1,105 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,071

Median for Nurse Practitioner: 389

Drug cost

$50,410

Median for Nurse Practitioner: $21,885

Branded share of claims

18.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Auvelity Dextromethorphan Hbr/Bupropion Brand 14 $14,227
Trintellix Vortioxetine Hydrobromide Brand 16 $12,484
Adderall Xr Dextroamphetamine/Amphetamine Brand 14 $5,710
Aripiprazole Generic 49 $5,582
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 47 $1,681
Mirtazapine Generic 41 $1,121
Duloxetine Hcl Generic 55 $1,052
Quetiapine Fumarate Generic 53 $949
Trazodone Hcl Generic 98 $908
Clonazepam Generic 117 $798

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$54,665

Medicare's payments for the services billed

Medicare patients

122

Average age 75

Services billed

966

94 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 72%
Arthritis 58%
Alzheimer's or dementia 44%
Diabetes 29%
COPD 28%
Ischemic heart disease 26%
Chronic kidney disease 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $440
$440 — —
CAPLYTA
  • ITI, Inc. $366
$366 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $209
$209 — —
Auvelity
  • Axsome Therapeutics, Inc. $131
$131 14 —
ONGENTYS
  • Amneal Pharmaceuticals LLC $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

240 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health, Adult in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record